Skip to main content

Ocrelizumab outperforms fingolimod after natalizumab cessation in RRMS

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Ocrelizumab outperforms fingolimod after natalizumab cessation in RRMS

User login

Username

Password

Reset your password

Type	Lead	score